Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Nature Medicine2015Vol. 21(7), pp. 795–801
Citations Over TimeTop 1% of 2015 papers
Giulia Siravegna, Benedetta Mussolin, Michela Buscarino, Giorgio Corti, Andrea Cassingena, Giovanni Crisafulli, Agostino Ponzetti, Chiara Cremolini, Alessio Amatu, Calogero Lauricella, Simona Lamba, Sebastijan Hobor, Antonio Avallone, Emanuele Valtorta, Giuseppe Rospo, Enzo Médico, Valentina Motta, Carlotta Antoniotti, Fabiana Tatangelo, Beatríz Bellosillo, Silvio Veronese, Alfredo Budillon, Clara Montagut, Patrizia Racca, Silvia Marsoni, Alfredo Falcone, Ryan B. Corcoran, Federica Di Nicolantonio, Fotios Loupakis, Salvatore Siena, Andrea Sartore‐Bianchi, Alberto Bardelli
Related Papers
- → Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab(2008)47 cited
- → Treatment with Panitumumab After a Severe Infusion Reaction to Cetuximab in a Patient with Metastatic Colorectal Cancer: A Case Report(2007)45 cited
- → The effectiveness of cetuximab and panitumumab when combined with FOLFIRI in second-line treatment of KRAS wild type metastatic colorectal cancers. Single centre experience(2020)2 cited
- → The Cost Study of Cetuximab and Panitumumab in The First-Line Treatment of Mcrc in The Czech Republic(2017)
- ASPECCT: panitumumab versus cetuximab for colorectal cancer(2014)